| abstract |
Disclosed herein are compounds that are effective in activating Tie-2 and inhibiting HPTP-beta. These compounds may provide an effective treatment for ocular conditions associated with angiogenesis, such as intraocular pressure, high intraocular pressure and glaucoma. In some embodiments, the invention provides a method for reducing intraocular pressure in a subject in need of reducing intraocular pressure, the method comprising administering a therapeutically effective amount of a Tie-2 activator. Administration to a subject, wherein the administration reduces intraocular pressure by about 0.1 mmHg to about 9 mmHg as compared to not administering. |